Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending February 2015. The report details the completion of an accelerated bookbuild offering involving GSK's entire shareholding in Genmab A/S ("Genmab").
Key Financial Metrics
- Transaction Proceeds: Gross proceeds of DKK 1,923 million (approximately GBP 194 million).
- Shares Sold: 4,471,202 shares, representing GSK's entire holding of approximately 7.9% of Genmab's share capital.
- Offer Price: DKK 430.00 per share.
- Exchange Rate: 9.92 DKK to 1 GBP.
- Other Metrics: The filing does not provide data on GSK's overall revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the divestiture of GSK's entire equity stake in Genmab. This transaction reduces GSK's exposure to Genmab and generates immediate cash proceeds of approximately GBP 194 million.
Outlook, Risks, and Unusual Items
Management Commentary: GSK confirmed the successful agreement of the sale with Deutsche Bank AG, London Branch acting as Sole Bookrunner.
Risks and Restrictions: The announcement includes significant legal disclaimers. The securities were not registered under the U.S. Securities Act of 1933. The information is not for distribution in the United States, Canada, Japan, or Australia. The transaction is directed only at "Qualified Investors" or "Relevant Persons" in the UK and EEA.
Investor Verification Checklist
- Verify the final settlement date and actual cash receipt of the GBP 194 million proceeds.
- Confirm the impact of this divestiture on GSK's consolidated financial statements for the quarter.
- Review the strategic rationale for exiting the Genmab investment in subsequent management commentary.
- Check for any remaining contractual obligations or earn-out provisions related to the Genmab stake.